Lorcaserin - Eisai Inc
Alternative Names: APD-356; Belviq; Belviq XR; E2023; Lorcaserin controlled-release; Lorcaserin extended-release; Lorcaserin hydrochloride; VenespriLatest Information Update: 05 Nov 2023
At a glance
- Originator Arena Pharmaceuticals
- Developer Arena Pharmaceuticals; CY Biotech; Eisai Inc; Ildong Pharmaceutical
- Class Antiepileptic drugs; Benzazepines; Obesity therapies; Small molecules
- Mechanism of Action 5-HT2C serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Obesity
- Phase III Dravet syndrome
- Clinical Phase Unknown Epilepsy
- Discontinued Smoking withdrawal
Most Recent Events
- 28 Nov 2022 Lorcaserin is still in the phase III MOMENTUM 1 trial for Dravet syndrome (In children) in USA, Canada (PO) (NCT04572243)
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 13 Nov 2021 Updated efficacy data from the phase III/IV CAMELLIA-TIMI 61 trial in Obesity presented at the American Heart Association Scientific Sessions 2021 (AHA-2021)